Selective CDK7 Inhibition for Therapy-Resistant Estrogen Receptor–Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer
Clin. Cancer Res 2024 Feb 21;[EPub Ahead of Print], C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, A Grinshpun, Q Zhang, A Freelander, MJ Leventhal, A Feit, G Cohen Feit, A Feiglin, W Liu, F Hermida-Prado, N Kesten, W Ma, C De Angelis, A Morlando, M O'Donnell, S Naumenko, S Huang, QD Nguyen, Y Huang, L Malorni, JS Bergholz Villafane, JJ Zhao, E Fraenkel, E Lim, R Schiff, GI Shapiro, R JeselsohnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.